Open access · OA
via OpenAlex
Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment
Dmitriy M. Niyazov, Stephan G. Kahler, Richard E. Frye
Molecular Syndromology · 2016 · ▲ 231 citations
Abstract
Mitochondrial disease refers to a heterogeneous group of disorders resulting in defective cellular energy production due to abnormal oxidative phosphorylation (oxphos). Primary mitochondrial disease (PMD) is diagnosed clinically and ideally, but not always, confirmed by a known or indisputably pathogenic mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutation. The PMD genes either encode oxphos proteins directly or they affect oxphos function by impacting production of the complex machinery needed to run the oxphos process. However, many disorders have the 'mitochondrial' phenotype without an identifiable mtDNA or nDNA mutation or they have a variant of unknown clinical significance. Secondary mitochondrial dysfunction(definition) (SMD) can be caused by genes encoding neither function nor production of the oxphos proteins and accompanies many hereditary non-mitochondrial diseases. SMD may also be due to nongenetic causes such as environmental factors. In our practice, we see many patients with clinical signs of mitochondrial dysfunction based on phenotype, biomarkers, imaging, muscle biopsy, or negative/equivocal mtDNA or nDNA test results. In these cases, it is often tempting to assign a patient's phenotype to 'mitochondrial disease', but SMD is often challenging to distinguish from PMD. Fortunately, rapid advances in molecular testing, made possible by next generation sequencing, have been effective at least in some cases in establishing accurate diagnoses to distinguish between PMD and SMD. This is important, since their treatments and prognoses can be quite different. However, even in the absence of the ability to distinguish between PMD and SMD, treating SMD with standard treatments for PMD can be effective. We review the latest findings regarding mitochondrial disease/dysfunction and give representative examples in which differentiation between PMD and SMD has been crucial for diagnosis and treatment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1159/000446586
- Canonical
- link ↗
- Fetched
- 2026-06-10 MST
Cite this
APA
Niyazov, D.M., Kahler, S.G., & Frye, R.E. (2016). Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. <em>Molecular Syndromology</em>. https://doi.org/10.1159/000446586
Vancouver
Niyazov DM, Kahler SG, Frye RE. Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Molecular Syndromology. 2016. doi:10.1159/000446586.
BibTeX
@article{dmitriy2016Primar,
title = {Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment},
author = {Dmitriy M. Niyazov and Stephan G. Kahler and Richard E. Frye},
journal = {Molecular Syndromology},
year = {2016},
doi = {10.1159/000446586},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
FEBS Letters 2017
Open access · OA
Mitochondrial <scp>DNA</scp> damage and reactive oxygen species in neurodegenerative disease
The Journal of Cell Biology 2011
Open access · OA
Mitochondrial DNA mutations in disease and aging
Aging Cell 2003
Open access · OA
The mitochondrial theory of aging: dead or alive?
Andrologia 2020
Open access · OA
Causes and consequences of sperm mitochondrial dysfunction
BMC Medicine 2015
Open access · CC-BY
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders
Molecular Neurodegeneration 2020
Open access · CC-BY